CSF3 and breast cancer: Second, it was necessary to focus on de novo stage IV breast cancer because earlier stage breast cancer almost always utilize G-CSF in neoadjuvant or adjuvant therapy but this may not represent the pattern of metastasis in other settings of patients with breast cancer.